< Terug naar vorige pagina
Onderzoeker
Sandra Tuyaerts
- Trefwoorden (Vrije Universiteit Brussel):Geneeskunde
- Disciplines (Vrije Universiteit Brussel):Kankerbiologie, Kankertherapie, Immunologie niet elders geclassificeerd
- Disciplines (KU Leuven):Gynaecologie en verloskunde, Verpleegkunde, Endocrinologie en metabole ziekten
- Zie ook: Sandra Tuyaerts (Vrije Universiteit Brussel)
Affiliaties
- Laboratorium Moleculaire Oncologie (Onderzoeksgroep)
Lid
Vanaf1 nov 2022 → Heden - Medische Oncologie (Departement)
Lid
Vanaf1 mei 2020 → Heden - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf1 feb 2021 → Heden - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf1 feb 2021 → 20 okt 2022 - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf1 jun 2020 → Heden - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf1 jun 2020 → 20 okt 2022 - Gynaecologische Oncologie (Afdeling)
Lid
Vanaf16 nov 2009 → 31 dec 2022 - Fysiologie (Departement)
Lid
Vanaf1 okt 1999 → 30 apr 2008 - Fysiologie (Departement)
Lid
Vanaf1 okt 1999 → 30 apr 2008
Publicaties
1 - 10 van 34
- Trial watch: Dendritic cell (DC)-based immunotherapy for cancer(2022)
Auteurs: Jenny Sprooten, Stefan Naulaerts, Benoit Beuselinck, An Coosemans, Lisa Kinget, Sandra Tuyaerts, Steven De Vleeschouwer, Abhishek Garg
- Intratumoral administration of CD1c (BDCA-1)(+) and CD141 (BDCA-3)(+) myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial(2022)
Auteurs: Sandra Tuyaerts
- Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells(2021)
Auteurs: Sandra Tuyaerts
- A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells (myDC) in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma(2021)
Auteurs: Sandra Tuyaerts
Pagina's: S832 - S833 - Intracranial administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in recurrent glioblastoma (rGB): A multi-cohort adaptive phase I clinical trial(2021)
Auteurs: Sandra Tuyaerts
Pagina's: S516 - S517 - Endometrial Cancer Molecular Characterization: The Key to Identifying High-Risk Patients and Defining Guidelines for Clinical Decision-Making?(2021)
Auteurs: Regina Esi Mensimah Baiden-Amissah, Daniela Annibali, Sandra Tuyaerts, Frédéric Amant
- Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?(2021)
Auteurs: Wout De Wispelaere, Daniela Annibali, Sandra Tuyaerts, Diether Lambrechts, Frédéric Amant
- Intratumoral Combinatorial Administration of CD1c (BDCA-1)(+) Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial(2020)
Auteurs: Sandra Tuyaerts
- Biological Function of PD-L2 and Correlation With Overall Survival in Type II Endometrial Cancer(2020)
Auteurs: Daniela Annibali, Sandra Tuyaerts, Frédéric Amant
- The Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer(2020)
Auteurs: Daniela Annibali, Sandra Tuyaerts, Frédéric Amant